Xiaoyun Shang

Chief executive officer, T-MAXIMUM Pharmaceutical

Appears in 1 story

Stories

FDA clears T-MAXIMUM's off-the-shelf CAR-T MT027 for Phase 2 brain metastasis study

Leading MT027 across two FDA Phase 2 programs

The FDA cleared T-MAXIMUM's off-the-shelf CAR-T, MT027, for a Phase 2 trial in brain metastases from lung and breast cancer. It's the second Phase 2 clearance for the therapy, which targets the tumor protein B7-H3 and is delivered directly into the brain.

Updated 1 hour ago